About Biovie (BIVI)
BioVie Inc. is a clinical stage biotechnology company engaged in the discovery, development and commercialization of therapies targeting life-threatening complications of liver cirrhosis. The Company's initial disease target is ascites a condition im... Read more
- USD6.00
- USD6.20
- USD5.74
- USD75.00
- -35.10%
- --
- 33.18k
- 49.42k
- 14M
- 6.00
- -84.60%
Stock News
7 hours ago
Consumer Sentiment Inches Up In July But Remains Historically Low
SeekingAlpha
yesterday
Cramer's week ahead: Earnings from Palantir, Berkshire Hathaway, Disney and McDonald's
CNBC
yesterday
Bonds and the dollar are sounding the alarm about the U.S. economy. Equity investors might want to listen.
MarketWatch
yesterday
Why Black entrepreneurs flock to Martha's Vineyard every August
CNBC
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
